The fully adjusted OR for MS, as predicted by plasma adiponectin and controlling for age, gender, and BMI was .928 (95% CI, .881–.977; p < .05), indicating that there was a 7% decrease in the odds of having MS for each 1 μg/mL increase in plasma adiponectin. Here, ADIPOQ is linked to myeloid sarcoma.